Catalent seeks slice of gene therapy market with Paragon buy

Contract drugmaker Catalent Inc said on Monday it would buy privately held Paragon Bioservices Inc for $1.2 billion in cash, bolstering its capabilities to make gene therapy drugs for its biotech clients.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news

Related Links:

In this study, rats received a severe contusive injury at the T9 segment of the spinal cord, followed by gene therapy with adenoassociated virus encoding human neurotrophic factor 3 (AAV-NT3) and a 2-week exercise program starting at 4 weeks after injury. We quantified the frequency of spasms during a swimming test at 4 and 6 weeks after injury and confirmed the results of the swimming test by measuring the H-reflex of the plantar muscle. We obtained weekly hind limb exercise scores to assess the effect of the interventions in hind limb motor function improvement. Then, we used immunofluorescence to observe the immunoreact...
Source: Neural Plasticity - Category: Neurology Authors: Tags: Neural Plast Source Type: research
ConclusionsThe results of this study demonstrate that lentivirus-mediated transfection of tumor suppressor genes exerts promising anti-tumor effects on RCC cell lines.
Source: Personalized Medicine Universe - Category: Drugs & Pharmacology Source Type: research
In conclusion, FGF21 belongs to a promising class of cytokines that are induced in response to stress and that can be used as a drug, drug target, or through a biomarker, depending on the physio-pathological context. All these findings will become clear when FGF21 will be used as a therapeutic molecule, exploiting the beneficial effects of FGF21 for treating metabolic disease or when it will be blocked to ameliorate disease progression and the onset of disease. Author Contributions CT and MS wrote the manuscript. VR contributed to the discussion. Funding This work was supported from the AFM-Telethon (19524), Italian Mi...
Source: Frontiers in Physiology - Category: Physiology Source Type: research
Human Gene Therapy Methods,Volume 30, Issue 2, Page 44-52, April 2019.
Source: Human Gene Therapy Methods - Category: Genetics & Stem Cells Authors: Source Type: research
Human Gene Therapy Methods,Volume 30, Issue 2, Page 60-69, April 2019.
Source: Human Gene Therapy Methods - Category: Genetics & Stem Cells Authors: Source Type: research
Cell therapy for Parkinson′s disease is coming of age: current challenges and future prospects with a focus on immunomodulationCell therapy for Parkinson′s disease is coming of age: current challenges and future prospects with a focus on immunomodulation, Published online: 16 April 2019; doi:10.1038/s41434-019-0077-4Cell therapy for Parkinson′s disease is coming of age: current challenges and future prospects with a focus on immunomodulation
Source: Gene Therapy - Category: Genetics & Stem Cells Authors: Source Type: research
Discussion In this section, we discuss the mechanisms responsible for lymphomagenesis in the various inborn errors of immunity and provide an overview of the treatment. Defects in Immune Responses That Predispose to Lymphomagenesis in PIDDs The complex immune mechanisms and their interplay that predisposes to neoplastic transformation of B or T cells and development of lymphomas in PIDD patients has not been fully elucidated. However, it is expected that the etiology in most cases is multifactorial and related to a dynamic regulation of immune response and environmental triggers (Figure 3). An underlying intrinsic susce...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Human Gene Therapy, Ahead of Print.
Source: Human Gene Therapy - Category: Genetics & Stem Cells Authors: Source Type: research
Human Gene Therapy, Ahead of Print.
Source: Human Gene Therapy - Category: Genetics & Stem Cells Authors: Source Type: research
The $1.2 billion deal is the latest designed to support the flood of gene therapies in development
Source: Chemical and Engineering News - Category: Chemistry Authors: Source Type: research
More News: Biotechnology | Contracts | Gene Therapy | Genetics | Health